Form 4: Akero Therapeutics Director, Seth Loring Harrison, Acquires 26,000 Stock Options

Director Seth Loring Harrison acquired 26,000 stock options in Akero Therapeutics, Inc. on June 8, 2024.

Summary

• On June 8, 2024, Seth Loring Harrison, a director of Akero Therapeutics, Inc., acquired 26,000 stock options at a price of $23.02.
• These options vest fully on the earlier of June 7, 2025, or the next annual meeting of the company's stockholders, contingent upon continued service on the Board.
• Following the transaction, Harrison directly owns 26,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, which is part of standard compensation.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the options is contingent upon the director's continued service on the Board, suggesting an expectation of ongoing involvement.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates